Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and Active ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Cipla Q3 Profit Surges 49% to Rs 1,571 Crore Cipla's net profit for Q3 FY25 jumped 49% to Rs 1,571 crore, driven by growth across markets. Revenue rose to Rs 7,073 crore. Read more. Jan 28, 2025 16:23 ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

Cipla is currently trading at Rs 1470.55, reflecting a notable increase of 2.35% today, with 1-day returns at 2.03%. Cipla is currently valued at Rs 1466.00, marking a 2.04% rise today. The one-year ...

Cipla's stock is priced at Rs 1472.4, reflecting a slight uptick of 0.07% today, with a six-month return of 3.38%. Cipla is currently trading at Rs 1469.15, showing a slight decline of 0.16% today, ...

Cipla reported a net profit of ₹1,303 crore, marking a 15% increase compared to the same period last year.

Return on investment - most recent fiscal year 16.16 ...

Erectile Dysfunction Drugs Market 2025 The global market is driven by factors such as an Increase in the prevalence of erectile dysfunction ...